RxDoctor Payments DataLook up a doctor →

Valerie Scott, MD

Family Medicine · Mt Pleasant, SCNPI 1700844461

Payments from drug & device makers

$22,861in general payments, 2019–2025

Across 1,209 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Pfizer$2K
  • AstraZeneca$2K
  • Amgen$1K
  • Lilly USA, LLC$1K
  • plus $11K from 54 others

What the payments were for

  • Food & beverage$22,832100%
  • Education$290%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)160$2,396
Novo Nordisk148$2,326
Pfizer123$1,872
AstraZeneca(2 entities)63$1,860
Amgen(2 entities)68$1,477
Lilly USA, LLC87$1,475
GSK45$907
Esperion Therapeutics, Inc.36$722
Axsome Therapeutics, Inc.27$629
Boehringer Ingelheim32$518
Otsuka America Pharmaceutical, Inc.27$511
Johnson & Johnson22$503
Biohaven Pharmaceuticals, Inc.19$498
Takeda Pharmaceuticals U.S.A., Inc.23$469
Gilead8$446
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC25$436
Lundbeck LLC18$378
Astellas Pharma US Inc17$346
Sanofi-aventis U.S. LLC16$325
Amarin Pharma, Inc.21$311
Teva Pharmaceuticals USA, Inc.18$277
Bayer13$254
Exact Sciences12$232
Novartis13$226
Corium, LLC10$224
Biohaven Pharmaceutical Holding Company Ltd.11$221
E.r. Squibb & Sons, L.L.C.7$216
Dexcom, Inc.6$185
Antares Pharma, Inc.9$170
Radius Health, Inc.3$161
Merck10$138
Paratek Pharmaceuticals, Inc.7$133
Abbott5$107
Jazz Pharmaceuticals Inc.6$106
Daiichi Sankyo Inc.5$105
Alnylam Pharmaceuticals Inc.5$98
Dermira, Inc.1$97
Eisai Inc.5$92
Supernus Pharmaceuticals, Inc.4$88
Shire North American Group Inc6$80
Kowa Pharmaceuticals America, Inc.6$78
Medtronic1$66
Noven Therapeutics, LLC3$65
Neos Therapeutics, LP4$62
Boston Scientific3$59
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$56
Halozyme Inc2$44
Genentech USA, Inc.3$43
Ultragenyx Pharmaceutical Inc.2$43
Idorsia Pharmaceuticals US Inc2$42
Aytu Biopharma, Inc.2$36
Renalytix AI, Inc.2$34
Collegium Pharmaceutical, Inc.2$34
Harmony Biosciences LLC1$33
Clarus Therapeutics Inc.3$31
Tolmar, Inc.2$31
Vanda Pharmaceuticals Inc.1$31
Ironwood Pharmaceuticals, Inc2$29
Adlon Therapeutics L.p.2$29
Kyowa Kirin, Inc.1$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,861 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$316,053
Medicare patients
536
Services billed
6,048

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide134$179,862
FarxigaDapagliflozin Propanediol90$113,343
EliquisApixaban61$58,527
JanuviaSitagliptin Phosphate44$54,007
JardianceEmpagliflozin31$41,390
MounjaroTirzepatide32$40,802
Repatha SureclickEvolocumab24$28,423
XareltoRivaroxaban24$22,326
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$13,765
Tresiba Flextouch U-100Insulin Degludec20$13,134
MyrbetriqMirabegron15$12,326
Tresiba Flextouch U-200Insulin Degludec11$10,239
Repatha SyringeEvolocumab13$6,715
Rosuvastatin Calcium426$6,425
Testosterone11$6,106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,326$179,862134 claims
AstraZenecaFarxiga$1,860$113,34390 claims
PfizerEliquis$1,872$58,52761 claims
MerckJanuvia$138$54,00744 claims
Boehringer IngelheimJardiance$518$41,39031 claims
Lilly USA, LLCMounjaro$1,475$40,80232 claims
Johnson & JohnsonXarelto$503$22,32624 claims
GSKTrelegy Ellipta$907$13,76518 claims
Astellas Pharma US IncMyrbetriq$346$12,32615 claims
AbbVieSynthroid$2,396$2,59236 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Mt Pleasant

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →